KRTX News and Press, Karuna Therapeutics Inc. From 11/27/19

Karuna Therapeutics ( KRTX ) announced that it had achieved positive results from its phase 2 study using KarXT to treat acute psychosis in patients with schizophrenia. There was a substantial improvement achieved in the primary endpoint of the study. This was not only an important finding...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Following the announcement of positive mid-phase testing for its schizophrenia treatment KarTX, Karuna Therapeutics, Inc. (NASDAQ: KRTX) enjoyed a 443% gain on November 18 and a 29.2% gain on November 19 to close at $123.99. That Tuesday's close represented a 6X+ gain over the previous Frida...

Written by Daniel Cohen and Scott Matusow Karuna Therapeutics (KRTX), NextCure (NXTC), and Constellation Pharmaceuticals (CNST) are but the latest examples of how the biotech sector has been heating up. All 3 of these names have seen very strong stock appreciation on earl...

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Andrew Miller, Ph.D.,...

Investment Thesis With the benefit of hindsight, the optimal time to have bought Karuna would have been any time between its IPO in June this year and before the results of its recent phase II clinical trials were announced. The company met its primary endpoint in trials of its flagship drug...

One biotech stock making recent headlines is Karuna Therapeutics (NASDAQ: KRTX) . This company, now with a market capitalization of $2.9 billion, has seen its shares skyrocket by over 700% since announcing impressive results for its schizophrenia drug candidate. It's definitely a big win f...

Gainers:  Wah Fu Education Group (NASDAQ: WAFU ) +203% . More news on: Wah Fu Education Group Limited, Hepion Pharmaceuticals, Inc., Stage Stores, Inc., Stocks on the move, Read more ...

Karuna Therapeutics ( KRTX -18.3% ) has priced its public offering of 2.6M common shares at $96.00 per share, for expected gross proceeds of ~$250M. More news on: Karuna Therapeutics, Inc., Healthcare stocks news, Read more ...

OptiNose (NASDAQ: OPTN )  -15%  on report of offering at 14.6% discount. More news on: OptiNose, Inc., BJ's Wholesale Club Holdings, Inc., Baozun Inc., Stocks on the move, Read more ...